World Disease Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of World Disease Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Positive phase II study of Bcl-2 antisense plus gemtuzumab ozogamicin reported
September 5th, 2006
Positive data has been reported from a phase II study of Bcl-2 antisense (Oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. According to recent research published in the journal Leukemia Research, "Oblimersen selectively targets Bcl-2 mRNA and has been shown to enhance the apoptotic activity of various antileukemic agents, including gemtuzumab ozogamicin (GO), in preclinical studies. We evaluated the efficacy and safety of oblimersen combined with GO in patients {{>=}}60 years of age in first relapse with CD33+ acute myeloid leukemia." "Oblimersen 7 mg/kg/day was given as...
Source: World Disease Weekly (2006-09-05)
|
